Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 3/20 | 0.82 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.82 |
| ▸ | FABP3 | P05413 | 1/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.57 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31156410 | 0.92 | FABP4 (0.97) | FABP4FABP5FABP3HDAC1HDAC6 | |
| SCHEMBL29114062 | 0.92 | FABP4 (0.97) | FABP4FABP5FABP3HDAC1HDAC6 | |
| SCHEMBL6833930 | 0.92 | FABP4 (0.97) | FABP4FABP5FABP3HDAC1HDAC6 | |
| SCHEMBL6419189 | 0.92 | FABP4 (0.97) | FABP4FABP5FABP3HDAC1HDAC6 | |
| SCHEMBL12951764 | 0.90 | FABP4 (1.00) | FABP4FABP5FABP3HDAC1HDAC6 | |
| SCHEMBL1415802 | 0.88 | FABP4 (0.64) | FABP4FABP5FABP3HDAC1HDAC6 | |
| SCHEMBL354562 | 0.88 | FABP4 (0.64) | FABP4FABP5FABP3HDAC1HDAC6 | |
| SCHEMBL354539 | 0.88 | FABP4 (0.64) | FABP4FABP5FABP3HDAC1HDAC6 | |
| SCHEMBL353478 | 0.88 | FABP4 (0.64) | FABP4FABP5FABP3HDAC1HDAC6 | |
| SCHEMBL353874 | 0.85 | FABP4 (0.60) | FABP4FABP5HDAC1HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184098-A1 | METHODS FOR MEASURING ENZYME ACTIVITY | GE HEALTHCARE UK LIMITED (GB) | 2010-07-22 | — | — | US | claimed |
| US-7727739-B2 | Methods for measuring enzyme activity | GE HEALTHCARE UK LIMITED (GB) | 2010-06-01 | — | — | US | claimed |
| EP-1497452-A2 | METHODS FOR MEASURING ENZYME ACTIVITY | Amersham Biosciences UK Limited (GB) | 2005-01-19 | — | — | EP | claimed |
| US-20030228609-A1 | Methods for measuring enzyme activity | TTP LABTECH LIMITED (GB) | 2003-12-11 | — | — | US | claimed |
| WO-2003089663-A2 | METHODS FOR MEASURING ENZYME ACTIVITY | AMERSHAM BIOSCIENCES UK LIMITED (GB) | 2003-10-30 | — | — | WO | claimed |
| CN-108473499-B | Novel pyrazolopyrimidine derivatives | 诺华股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20200289514-A1 | Novel Pyrazolo Pyrimidine Derivatives | NOVARTIS PHARMA AG (CH) | 2020-09-17 | — | — | US | disclosed |
| US-10442808-B2 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors | NOVARTIS AG (CH) | 2019-10-15 | — | — | US | disclosed |
| EP-3149001-B1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHIBITORS | NOVARTIS AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| EP-3374361-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2018-09-19 | — | — | EP | disclosed |
| US-20180030061-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-9815842-B2 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| EP-1649283-A2 | METHOD FOR MEASURING AROMATASE ACTIVITY | GE Healthcare UK Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005012901-A2 | METHOD FOR MEASURING AROMATASE ACTIVITY | AMERSHAM BIOSCIENCES UK LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| EP-1497452-A2 | METHODS FOR MEASURING ENZYME ACTIVITY | Amersham Biosciences UK Limited (GB) | 2005-01-19 | — | — | EP | disclosed |
| US-20040191792-A1 | Acridone derivatives as labels for fluorescence detection of target materials | GE HEALTHCARE UK LIMITED (GB) | 2004-09-30 | — | — | US | disclosed |
| EP-1392776-A2 | ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS | Amersham Biosciences UK Limited (GB) | 2004-03-03 | — | — | EP | disclosed |
| US-20030228609-A1 | Methods for measuring enzyme activity | TTP LABTECH LIMITED (GB) | 2003-12-11 | — | — | US | disclosed |
| WO-2003089663-A2 | METHODS FOR MEASURING ENZYME ACTIVITY | AMERSHAM BIOSCIENCES UK LIMITED (GB) | 2003-10-30 | — | — | WO | disclosed |
| WO-2002099424-A2 | ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS | AMERSHAM BIOSCIENCES UK LIMITED (GB) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030061-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | MMEL1, MALT1, FBP1 | FABP4 4332/4885FABP5 3183/4885FABP3 3401/4885 |
| US-20200289514-A1 | Novel Pyrazolo Pyrimidine Derivatives | MMEL1, PPME1, CTSC | FABP4 4534/4885FABP5 3591/4885FABP3 3917/4885 |
| US-20040191792-A1 | Acridone derivatives as labels for fluorescence detection of target materials | ACR, ARSA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | FABP4 1027/4885FABP5 905/4885FABP3 862/4885 |
| US-10442808-B2 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors | FBP1, MMEL1, MALT1 | FABP4 4306/4885FABP5 2644/4885FABP3 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.